ReviewFuture cardiology2025
Cross-pollination of two specialties: potential repurposing of cancer and cardiovascular drugs for the benefit of the other.
Review in Future cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advancements in treatment, cancer and cardiovascular disease remain the leading causes of morbidity and mortality in developed nations. Cancer therapies have led to improved cancer-specific outcomes at the potential risk of cardiotoxicity. Additionally, basic and translational research have demonstrated a common shared pathophysiology of cancer and cardiovascular disease. Recent clinical research has suggested a potential role of repurposing cancer and cardiovascular medications for the treatment of each other. This narrative review aims to review and examine current literature of repurposing cancer and cardiovascular drugs via exploitation of off-target effects to benefit each condition. A better understanding of underlying pathophysiologic effects of these off-target mechanisms of action may aid in identifying novel therapeutics for both cancer and cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.